在阿尔茨海默氏症中准微质:病原和潜在的治疗策略
Zhongqing Sun1,2,3, Xin Zhang1, Kwok-Fai So3,4,5
1Department of Neurology, Xijing Hospital, Fourth Military Medical University, Xi'an 710032, China.
Biomolecules
|July 27, 2024
概括
微质细胞,大脑的免疫细胞,在阿尔茨海默病 (AD) 中表现出改变的功能,损害粉样蛋白清除并促进炎症. 准这些微质细胞为阿兹海默症治疗提供了有希望的治疗策略.
科学领域:
- 神经科学是一个神经科学.
- 免疫学 免疫学 免疫学
- 基因组学就是基因组学.
背景情况:
- 中枢神经系统的寄居性巨细胞 (microglia) 在阿尔茨海默氏病 (AD) 发病过程中至关重要.
- 它们在粉样β (Aβ) 斑块周围的聚集是AD的标志.
- 最近的单细胞测序揭示了衰老和AD进展过程中微质表型的动态变化.
研究的目的:
- 阐明微质在阿尔茨海默病中的多方面的作用.
- 探索针对AD的微质功能障碍的治疗策略.
- 突出AD治疗新方法的潜力.
主要方法:
- 使用了单细胞RNA测序 (scRNA-seq) 和单核RNA测序 (snRNA-seq).
- 分析不同大脑区域和疾病阶段的微质表现型.
- 审查针对微质细胞的当前和新兴治疗策略.
主要成果:
- 晚期AD患者的微质细胞表现出Aβ和tau的化功能受损.
- 微质细胞释放的促炎性细胞因子有助于突触和神经元损伤.
- scRNA-seq和snRNA-seq数据显示了微质状态的动态变化.
结论:
- 微质功能障碍显著导致AD的发病.
- 专注于增强微细胞化和减少神经炎症的治疗策略对阿尔茨海默病有希望.
- 对微质动力学和天然产品干预的进一步研究可以促进AD治疗.
更多相关视频
相关概念视频
01:22Alzheimer's Disease: Treatment
172
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
172
01:26Alzheimer's Disease: Overview
456
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
456